NO20092116L - Alfa-substituerte omega-3 lipider som er aktivatorer eller modulatorer for den peroksisom-proliferatoraktiverte reseptoren (PRAR) - Google Patents
Alfa-substituerte omega-3 lipider som er aktivatorer eller modulatorer for den peroksisom-proliferatoraktiverte reseptoren (PRAR)Info
- Publication number
- NO20092116L NO20092116L NO20092116A NO20092116A NO20092116L NO 20092116 L NO20092116 L NO 20092116L NO 20092116 A NO20092116 A NO 20092116A NO 20092116 A NO20092116 A NO 20092116A NO 20092116 L NO20092116 L NO 20092116L
- Authority
- NO
- Norway
- Prior art keywords
- group
- compounds
- prar
- activators
- modulators
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 lipid compounds Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000003857 carboxamides Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000007942 carboxylates Chemical class 0.000 abstract 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/54—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85573306P | 2006-11-01 | 2006-11-01 | |
| SE0602310 | 2006-11-01 | ||
| PCT/IB2007/003305 WO2008053331A1 (fr) | 2006-11-01 | 2007-11-01 | Lipides oméga-3 à substitution alpha en tant qu'activateurs ou modulateurs du récepteur activé par proliférateurs de peroxisome (ppar) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092116L true NO20092116L (no) | 2009-05-29 |
Family
ID=39343866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092116A NO20092116L (no) | 2006-11-01 | 2009-05-29 | Alfa-substituerte omega-3 lipider som er aktivatorer eller modulatorer for den peroksisom-proliferatoraktiverte reseptoren (PRAR) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8399516B2 (fr) |
| EP (1) | EP2094640A4 (fr) |
| JP (1) | JP5552313B2 (fr) |
| KR (1) | KR101438177B1 (fr) |
| CN (1) | CN101535238A (fr) |
| CA (1) | CA2667211A1 (fr) |
| MX (1) | MX2009004336A (fr) |
| NO (1) | NO20092116L (fr) |
| WO (1) | WO2008053331A1 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006117668A1 (fr) | 2005-05-04 | 2006-11-09 | Pronova Biopharma Norge As | Analogues d'acides gras, autrement dit derives dha utilises comme medicament |
| MX2009004337A (es) * | 2006-11-01 | 2009-05-22 | Pronova Biopharma Norge As | Compuestos lipidos omega-3. |
| EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
| WO2009056983A1 (fr) * | 2007-10-31 | 2009-05-07 | Pronova Biopharma Norge As | Nouveaux dérivés de dha et leur utilisation en tant que médicaments |
| WO2009061208A1 (fr) * | 2007-11-09 | 2009-05-14 | Pronova Biopharma Norge As | Composés lipidiques à utiliser dans des produits cosmétiques, en tant que suppléments alimentaires ou en tant que médicaments |
| WO2009134147A1 (fr) * | 2008-05-02 | 2009-11-05 | Pronova Biopharma Norge As | Compositions lipidiques renfermant des dérivés d’epa et de dha et leur utilisation |
| EP2147910A1 (fr) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Nouveaux composés lipidiques |
| ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| BRPI1015120B8 (pt) | 2009-05-08 | 2022-02-15 | Basf As | Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico |
| WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
| WO2011149766A2 (fr) * | 2010-05-23 | 2011-12-01 | Jingxuan Kang | Agents pharmaceutiques à lipides personnalisés |
| BR112012031194A2 (pt) * | 2010-06-08 | 2018-05-29 | Krisani Biosciences P Ltd | derivados de cisteamina e seu uso no tratamento de ehna |
| EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| ES2618604T3 (es) | 2010-11-05 | 2017-06-21 | Pronova Biopharma Norge As | Métodos de tratamiento usando compuestos lipídicos |
| US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
| WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
| PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| EP2861227A4 (fr) | 2012-06-17 | 2016-01-27 | Matinas Biopharma Inc | Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation |
| WO2014008379A2 (fr) * | 2012-07-06 | 2014-01-09 | Thetis Pharmaceuticals Llc | Formes salines diamine et méglumine d'acides gras |
| US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| WO2014057438A2 (fr) * | 2012-10-13 | 2014-04-17 | Mahesh Kandula | Compositions et méthodes de traitement de maladies cardiovasculaires |
| WO2014083528A2 (fr) * | 2012-12-02 | 2014-06-05 | Mahesh Kandula | Compositions et méthodes pour le traitement de maladies cardio-vasculaires et de troubles lipidiques |
| MX377728B (es) | 2013-02-28 | 2025-03-11 | Pronova Biopharma Norge As | Composición que comprende un compuesto lípido, un triglicerido y un tensioactivo, y métodos de uso de la misma. |
| CA2947741A1 (fr) | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions et procedes se rapportant a des sels ioniques de peptides |
| US20150344402A1 (en) * | 2014-05-28 | 2015-12-03 | Jiva Pharma, Inc. | Omefibrates for Treating Dyslipidemia and Cardiovascular Disease |
| US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
| US9999626B2 (en) | 2014-06-18 | 2018-06-19 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of active agents |
| JP6348229B2 (ja) * | 2014-10-21 | 2018-06-27 | ユニバーシタット デ レス イレス バレアレス | ヒドロキシ−トリグリセリドの合成方法、および疾患の予防および処置のためのその使用 |
| PL3233074T3 (pl) * | 2014-12-15 | 2023-02-06 | Dsm Ip Assets B.V. | Leczenie niealkoholowych stłuszczeniowych chorób wątroby |
| ES2980790T3 (es) | 2015-04-28 | 2024-10-03 | Basf As | Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| WO2016205691A1 (fr) | 2015-06-19 | 2016-12-22 | Massachusetts Institute Of Technology | 2,5-pipérazinediones substituées par un alcényle, et leur utilisation dans des compositions destinées à l'administration d'un agent à un sujet ou une cellule |
| GB201521085D0 (en) * | 2015-11-30 | 2016-01-13 | Biozep As | Use |
| US10125078B1 (en) * | 2015-12-28 | 2018-11-13 | Jiva Pharma Inc. | NSAID derivatives of omega-3 polyunsaturated acids as gamma secretase modulators |
| ES2827796T3 (es) | 2016-06-03 | 2021-05-24 | Thetis Pharmaceuticals Llc | Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación |
| IL308604B2 (en) | 2017-12-06 | 2025-08-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| CN116617201A (zh) * | 2023-06-02 | 2023-08-22 | 延边大学 | 二十碳三烯酸在调节机体炎症中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2836628A (en) | 1955-10-17 | 1958-05-27 | Monsanto Chemicals | Unsaturated branched-chain alcohols and methods of preparing same |
| US4132719A (en) | 1978-04-20 | 1979-01-02 | Mcneilab Inc. | Dibromoalkylglycidic acid derivatives |
| US4264517A (en) * | 1978-12-11 | 1981-04-28 | G.D. Searle & Co. | Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates |
| JPS57149400A (en) | 1981-03-12 | 1982-09-14 | Kureha Chemical Ind Co Ltd | Manufacture of high purity long chain highly unsaturated fatty acid ester |
| JPS59204175A (ja) | 1983-04-28 | 1984-11-19 | Terumo Corp | ５―フルオロウラシル誘導体を有効成分とする血小板凝集抑制剤 |
| US4647685A (en) | 1985-04-25 | 1987-03-03 | Eli Lilly And Company | 2-alkoxy-1-((2-trialkylaminoethoxy)phosphinyloxy)-alkenes and alkynes, hydroxy inner salts |
| JPS6388159A (ja) | 1986-09-30 | 1988-04-19 | Nippon Oil & Fats Co Ltd | ドコサヘキサエン酸エステルの製造法 |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| JPH05974A (ja) | 1991-06-21 | 1993-01-08 | Sagami Chem Res Center | ハロゲン化不飽和アルキル化合物及びその前駆体 |
| US5422371A (en) | 1992-05-27 | 1995-06-06 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
| JPH06240289A (ja) | 1992-06-09 | 1994-08-30 | Bizen Kasei Kk | ドコサヘキサエン酸エチルエステルを含有する脂肪酸エチルエステル混合物の製造方法 |
| JPH06293789A (ja) | 1993-04-08 | 1994-10-21 | Teijin Ltd | 多価不飽和脂肪酸類配糖体およびその製造方法 |
| JPH0753488A (ja) | 1993-08-10 | 1995-02-28 | Aiwa:Kk | ドコサヘキサエン酸誘導体 |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| JPH10195023A (ja) | 1997-01-13 | 1998-07-28 | Shiseido Co Ltd | 新規高度不飽和脂肪酸エチルエステル |
| US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
| US6153653A (en) | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
| WO1999058120A1 (fr) | 1998-05-08 | 1999-11-18 | Rolf Berge | Utilisation d'analogues d'acides gras non beta-oxydables pour traiter les etats lies au syndrome x |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| GB9918023D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
| JP4530311B2 (ja) | 2000-07-13 | 2010-08-25 | 日本水産株式会社 | リパーゼを用いたグリセライドの製造方法 |
| JP2002180082A (ja) | 2000-12-11 | 2002-06-26 | Maruha Corp | 摂取物 |
| IT1320180B1 (it) | 2000-12-29 | 2003-11-26 | Hunza Di Marazzita Maria Carme | Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e |
| ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| JP3934968B2 (ja) | 2002-03-25 | 2007-06-20 | 富士フイルム株式会社 | 色変換定義作成方法、色変換定義作成装置、および色変換定義作成プログラム |
| CN1665496B (zh) | 2002-05-03 | 2010-05-05 | 派普生物保健品公司 | Epa和dha在制备二级预防神经性疾患的药物中的用途 |
| TW200412942A (en) | 2002-08-06 | 2004-08-01 | Abbott Lab | Appetite control method |
| EP1544281B1 (fr) | 2002-08-07 | 2016-10-05 | Kao Corporation | Composition de corps gras |
| NO319194B1 (no) | 2002-11-14 | 2005-06-27 | Pronova Biocare As | Lipase-katalysert forestringsfremgangsmate av marine oljer |
| JP2004182674A (ja) | 2002-12-05 | 2004-07-02 | Kureha Chem Ind Co Ltd | バニリル脂肪酸アミドを含む抗腫瘍医薬組成物 |
| WO2004071504A1 (fr) | 2003-02-12 | 2004-08-26 | Galderma Research & Development, S.N.C. | Composes modulateurs des recepteurs du type ppar et leur utilisation dans des preparations pharmaceutiques et cosmetiques |
| WO2004078166A2 (fr) * | 2003-03-05 | 2004-09-16 | Solvay Pharmaceuticals Gmbh | Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques |
| MY144341A (en) | 2003-03-27 | 2011-08-29 | Suntory Holdings Ltd | Lipid-improving agent and composition containing lipid-improving agent |
| EP1466597A1 (fr) | 2003-04-07 | 2004-10-13 | Clinigenetics | Usage d'estères du dha pour le traitement des maladies vasculaires |
| TW200505425A (en) | 2003-05-29 | 2005-02-16 | Schering Plough Ltd | Compositions and method for treating infection in cattle and swine |
| SE0303513D0 (sv) | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| US20060135610A1 (en) | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| WO2006117668A1 (fr) | 2005-05-04 | 2006-11-09 | Pronova Biopharma Norge As | Analogues d'acides gras, autrement dit derives dha utilises comme medicament |
| GB0605900D0 (en) | 2006-03-23 | 2006-05-03 | Lipigen As | Modulators of nuclear receptors |
| ES2391305T3 (es) | 2006-04-12 | 2012-11-23 | Unilever N.V. | Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel |
| US20110166228A1 (en) * | 2006-11-01 | 2011-07-07 | Anne Kristin Holmeide | Composition |
| DK2315740T3 (en) | 2008-07-08 | 2018-01-08 | Catabasis Pharmaceuticals Inc | Fatty Acid Acetylated Salicylates and Their Uses |
-
2007
- 2007-11-01 KR KR1020097011198A patent/KR101438177B1/ko not_active Expired - Fee Related
- 2007-11-01 EP EP07825558.5A patent/EP2094640A4/fr not_active Withdrawn
- 2007-11-01 US US12/446,615 patent/US8399516B2/en not_active Expired - Fee Related
- 2007-11-01 WO PCT/IB2007/003305 patent/WO2008053331A1/fr not_active Ceased
- 2007-11-01 JP JP2009533980A patent/JP5552313B2/ja not_active Expired - Fee Related
- 2007-11-01 MX MX2009004336A patent/MX2009004336A/es active IP Right Grant
- 2007-11-01 CN CNA2007800408644A patent/CN101535238A/zh active Pending
- 2007-11-01 CA CA002667211A patent/CA2667211A1/fr not_active Abandoned
-
2009
- 2009-05-29 NO NO20092116A patent/NO20092116L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010508259A (ja) | 2010-03-18 |
| US8399516B2 (en) | 2013-03-19 |
| EP2094640A1 (fr) | 2009-09-02 |
| EP2094640A4 (fr) | 2015-05-20 |
| CN101535238A (zh) | 2009-09-16 |
| US20100035990A1 (en) | 2010-02-11 |
| WO2008053331A1 (fr) | 2008-05-08 |
| MX2009004336A (es) | 2009-05-22 |
| KR101438177B1 (ko) | 2014-09-05 |
| CA2667211A1 (fr) | 2008-05-08 |
| JP5552313B2 (ja) | 2014-07-16 |
| KR20090087458A (ko) | 2009-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092116L (no) | Alfa-substituerte omega-3 lipider som er aktivatorer eller modulatorer for den peroksisom-proliferatoraktiverte reseptoren (PRAR) | |
| UA109252C2 (uk) | Сірковмісні ліпіди для застосування як харчових добавок або медикаментів | |
| CY1113269T1 (el) | Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων | |
| GEP20135907B (en) | L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators | |
| UA93393C2 (uk) | 1,3-діоксанкарбонові кислоти | |
| MY148096A (en) | 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments | |
| NO20071577L (no) | Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer | |
| MY148483A (en) | 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments | |
| WO2008127349A3 (fr) | Composés organiques | |
| TN2013000309A1 (en) | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents | |
| BR122015028990B8 (pt) | composto, composições fungicidas e método de controle de doenças das plantas | |
| EA200970090A1 (ru) | Модуляторы метаболизма и лечение связанных с ним расстройств | |
| WO2008142482A3 (fr) | Composition | |
| NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| UY28493A1 (es) | Metanosulfonato del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico y su utilización como medicamento. | |
| NO20091620L (no) | Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser | |
| MY162502A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| NO20090064L (no) | Pyrasoler som glucokinase aktivatorer | |
| NO20092117L (no) | Nye lipidforbindelser | |
| MX2010009462A (es) | Derivados de indazol. | |
| UY30533A1 (es) | Acetamidas n-{1-[4(1-ciano-1-metil)fenil]etil}sustituidas derivadas del acido 2-(1h-bencimidazol-1il) acético | |
| IN2014DN03155A (fr) | ||
| MX2010004362A (es) | Derivados 1,2,4-triazol amino como moduladores de receptores de glutamato metabotropicos (mglur5). | |
| MX2009012713A (es) | Nuevos derivados de acido 3-fenil acrilico de receptores de tipo ppar, su metodo de preparacion y su uso en composiciones cosmeticas o farmaceuticas. | |
| GEP20135804B (en) | Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |